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Abstract  
Purpose: Papillary thyroid cancer (PTC) patients treated with thyroidectomy and radioiodine remnant ablation (RRA) often 
have detectable TSH-stimulated thyroglobulin (Tg) levels without localizable disease after primary treatment. To assess the 
value of repeat stimulated Tg assays in these patients’ follow-up, we retrospectively analyzed 86 cases followed in 8 Italian 
thyroid-cancer referral centers.  
Methods: We enrolled 86 patients with PTCs treated with total/near-total thyroidectomy plus RRA between 1 January 1990 
and 31 January 2006. In all cases, the initial postoperative visit revealed stimulated serum Tg >1 ng/mL, negative Tg 
antibodies, and no structural evidence of disease. None received empiric radioiodine therapy. Follow-up (median: 9.6 yrs) 
included neck ultrasound and basal Tg assays (yearly) and at least 1 repeat stimulated Tg assay. 
Results: Of the 86 patients analyzed (initial risk: low 63%, intermediate 35%, high 2%), one (1%) had ultrasound-detected 
lymph-node disease and persistently elevated stimulated Tg levels at 3 years. In 17 (20%), imaging findings were 
consistently negative, but the final stimulated Tg levels was still >1 ng/mL (median 2.07 ng/mL, range 1.02–4.7). The other 
68 (80%) appeared disease-free (persistently negative imaging findings with stimulated Tg levels ≤1 ng/mL. Mean intervals 
between first and final stimulated Tg assays were similar (5.2 and 4.8 years) in subgroups with vs. without Tg 
normalization. Reclassification as disease-free was significantly more common when initial stimulated Tg levels were 
indeterminate (<10 ng/mL). 
Conclusions: In unselected PTC cohorts with incomplete/indeterminate biochemical responses to thyroidectomy and RRA, 
periodic re-measurement of stimulated Tg allows most patients to be classified as disease-free. 
 
Key words: papillary thyroid cancer, thyroglobulin, biochemical incomplete response, indeterminate response, follow-up, 
recurrences   
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Introduction 
The incidence of papillary thyroid cancers (PTC) has tripled since the mid-1970s [1], but outcomes are good in the 
vast majority of cases (approximately 98% according to the Surveillance, Epidemiology, and End Results Program 
Database). Nevertheless, life-long surveillance is still the rule in many centers because disease recurrence has been observed 
as late as 40 years after the diagnosis [2,3].  
The cornerstones of the surveillance process are the neck ultrasound examination and assays of serum levels of 
thyroglobulin (Tg), which is produced exclusively by follicular thyrocytes. The serum Tg assay is a widely available, low-
cost procedure with high sensitivity and specificity for detecting persistent or recurrent thyroid cancer [4]. However, 
detectable Tg levels may reflect the residual presence of normal thyrocytes and/or the persistence or recurrence of 
neoplastic thyroid tissue. This diminishes the specificity of the marker, particularly in the growing population of PTC 
patients who do not undergo postoperative radioiodine remnant ablation (RRA) [5]. However, Tg assay positivity (without 
structural evidence of disease) is also reported in up to 36% of the PTC patients who do undergo ablation [6-10]. As for 
sensitivity, serum Tg assays may also fail to identify small volumes of neoplastic thyroid tissue, especially when they are 
performed during thyroid hormone suppression of thyroid-stimulating hormone (TSH). Measurement of TSH-stimulated 
levels of Tg is thus recommended to maximize sensitivity [4]. This approach is complicated by the fact that withdrawal of 
thyroid hormone replacement therapy—the method traditionally used to increase TSH levels—subjects patients to the 
unpleasant symptoms of hypothyroidism for approximately 3-6 weeks [11]. This problem can now be avoided with the use 
of recombinant human TSH (rhTSH) [12], although the gain in tolerability is offset to some extent by a non-negligible cost 
increase related to the price of the drug.  
These considerations justify attempts to rationalize the use of stimulated Tg testing during follow-up of patients 
with PTCs. Repetition of these assays is of little benefit once the patient meets the criteria for classification as disease-free 
[13-16]. For those treated with total/near-total thyroidectomy followed by RRA, this means the absence of clinical and 
imaging evidence of tumor (i.e., neck US and/or diagnostic 131I whole-body scan [dxWBS]) and basal and stimulated Tg 
levels that are ≤1 ng/mL, in the absence of thyroglobulin antibodies (TgAb) [4]. The negative predictive value of all of these 
findings is almost 100% [17-19]. Clinical or imaging (cross-sectional or functional) findings compatible with persistent 
macroscopic disease usually prompt additional treatment or at least a more active form of surveillance [4]. There is no 
consensus, however, regarding the management of individuals with detectable Tg levels in the absence of localizable 
disease, and the benefit from repeating TSH-stimulated testing in this patient population is uncertain. Reported outcomes in 
these cases vary widely, with imaging-documented evidence of disease emerging in 8-50% of patients. In similar 
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percentages (13-50%), however, the Tg level reportedly diminishes progressively and at some point becomes undetectable, 
thereby allowing the patient to be classified as disease-free [6-10].  
The goals of the present study were: 1) to shed light on the natural course of PTC associated with detectable 
stimulated Tg levels in the absence of localizable disease as the best response at the initial post-treatment assessment and 2) 
to assess the value of repeated assay of TSH-stimulated Tg levels in the follow-up of these patients.  
 
Patients and Methods 
Study design and setting 
This retrospective, observational study was conducted with institutional review board approval in 8 hospital-based 
primary thyroid-cancer referral centers in Italy (2 nuclear medicine units, 6 thyroid disease units). Since 1990, these centers 
have used similar protocols for the post-operative follow-up of patients with PTC. For those who undergo total or near total 
thyroidectomy with RRA (the focus of the present study), the first follow-up visit is scheduled 6-18 months after the initial 
treatment. It includes assays of basal and TSH-stimulated serum Tg levels (with simultaneous assessment of TgAb levels) 
and neck ultrasound studies performed with multifrequency probes [7.5 - 12 MHz] by an experienced staff endocrinologist. 
In the past, dxWBS was also performed routinely during the first visit in some centers, but since 2006 this procedure has 
been used only as a second-line study [20]. Subsequent visits are scheduled yearly and include basal Tg assay, TgAb levels, 
and neck ultrasound. If the stimulated Tg assay is positive at the initial visit, it is repeated periodically (frequency at the 
discretion of the physician) as long as levels remain in the detectable range. Additional functional and/or cross-sectional 
imaging studies are ordered as needed. If suspicious lymph nodes are found and are eligible for surgical removal, fine 
needle aspiration biopsy is performed for cytology, measurement of Tg levels in the needle washout fluid, and since 1997, 
high-sensitivity assay of washout fluid for Tg and TSH mRNA [21,22]. All Tg and TgAb assays are done in the center's 
own laboratory. 
 
Cohort selection 
We reviewed the thyroid cancer databases of each participating center and identified patients consecutively 
diagnosed with PTC between 1 January 1990 and 31 January 2006 who met all the following eligibility criteria: 1) primary 
treatment consisting of total or near-total thyroidectomy followed by RRA; 2) surgical pathology report confirming 
diagnosis of PTC; 3) all diagnostic procedures during follow-up carried out by the staff of the participating study center; 4) 
all serum Tg values measured with immunometric assay with a functional sensitivity of 1 ng/mL or less and accompanied 
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by negative Tg antibody assay results; 5) complete findings for each year of follow-up (in accordance with the protocol 
described above).  From this set of patients, we then selected those with 1) a stimulated serum Tg level of >1 ng/mL and 
negative clinical or imaging findings at the first postoperative visit; and 2) at least one other stimulated Tg assay performed 
≤10 years after the first. To focus on the natural history of these tumors during follow-up, we then excluded from our 
analysis any cohort members who had received further therapy after the primary treatment.  
 
Data collection and end points 
Data on cohort patients were collected from the medical records and stored in an electronic database. They 
included demographics, data on the primary treatment (surgery and RRA), tumor characteristics, documentation of 
structural disease during the follow-up period, and any additional treatments that were performed. The prespecified primary 
endpoint was the spontaneous decline of the stimulated Tg level to ≤1 ng/mL in the presence of persistently negative 
findings on neck ultrasound and on any other imaging studies that may have been performed (i.e., the criteria for 
classification as disease-free established by the American Thyroid Association) [4]. The secondary endpoints were assessed 
at the end of follow-up and included 1) the persistence of stimulated Tg levels > 1 ng/mL and 2) the emergence of 
clinical/imaging evidence of disease.  
 
Statistical analysis 
Differences between categorical variables (expressed as numbers and percentages) were evaluated with the chi-
square test or the Fischer Exact test for small samples; differences between continuous variables (reported as medians and 
ranges) were assessed with the Mann Whitney test. A P value <0.05 was considered statistically significant.  Stat view 5.0.1 
software (SAS Institute inc., Cary, North Carolina) was used for all statistical analyses. 
 
Results 
 
As shown in Figure 1, of the 365 patients who met the eligibility criteria, 93 (26%) had TSH-stimulated serum Tg 
levels > 1 ng/mL with no structural evidence of disease at the first (1-year) postoperative assessment and at least one other 
stimulated Tg assay during follow-up. The 7 patients in this group who received additional radioiodine therapy were 
excluded from further analysis, leaving a study cohort of 86 patients. Their baseline characteristics are summarized in Table 
1.  
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The final stimulated serum Tg assay in the study cohort was performed 1–10 years after the first (median: 5.1 
years). TSH stimulation was achieved with LT4 withdrawal in 34 cases and the administration of rhTSH in the other 52 
cases. In 42 (49%) cases, the same stimulation method was used for the first and final Tg assays (LT4 withdrawal in 34 
cases, rhTSH injection in 8) (see Table 1). In the remaining 44 (51%), the initial assay had been done after LT4 withdrawal 
and the final assay after rhTSH administration (see Table 1). At this point (Figure 1), 68 (80%) of the 86 patients presented 
stimulated (and basal) Tg levels that were ≤1 ng/mL together with persistently negative findings on physical examination, 
neck ultrasound, and any other imaging studies performed. In accordance with ATA Guidelines [4], these patients were thus 
re-classified as apparently disease-free, and monitoring of stimulated Tg levels was discontinued. In 17 other cases (19%), 
the physical examination and neck ultrasound study were still negative, but the stimulated Tg levels remained above the 1 
ng/mL cut-off (median 2.07 ng/mL, range 1.02 – 4.7). The mean interval between the first and last stimulated Tg assays in 
this group was not significantly different from that of the group with assay negativization (4.8 years vs. 5.2 years, Mann 
Whitney test, p = 0.71). 
As for the final patient in the study cohort (Figure 1), he had undergone total thyroidectomy, central neck 
dissection, and RRA (activity 106 mCi) at age 20 for an intermediate-risk (pT3, pN1a) PTC. The first postoperative 
assessment had revealed an rhTSH-stimulated Tg level of 1.05 ng/mL with negative findings on both neck ultrasound and 
dxWBS. Three years later, the rhTSH-stimulated Tg level was reassessed and found to be 1.24 ng/mL. Suspicious lymph 
nodes were noted on neck US and cytologically confirmed to be PTC metastases. After discussion of the pros and cons of a 
second operation, the patient opted for active surveillance instead. In the 2.5 years that have passed since that time (5.6 
years since the initial treatment), neck ultrasound studies performed at intervals of 6-12 months have revealed no change 
whatsoever in the size or appearance of lymph node lesions. At the final follow-up visit (median 8.2 years [range 3.5 to 19.5 
years] after the first assessment, 9.6 years [range 4 to 21 years] after diagnosis), this patient was still the only one in the 
study cohort with documented evidence of structural recurrence.  
As shown in Table 2, the likelihood of being reclassified as disease-free during follow-up was significantly greater 
in patients whose initial stimulated Tg levels were <10 ng / mL (i.e., those falling into the indeterminate range) [23]. It was 
not significantly related to the initial American Thyroid Association (ATA) risk class or to the radioiodine dose used for 
remnant ablation. 
 
Discussion 
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In this retrospective, multicenter study we investigated the natural course of PTC in 86 patients whose initial 
assessment after primary treatment (total thyroidectomy + RRA) revealed TSH-stimulated serum Tg levels > 1 ng/mL in the 
absence of localizable disease. This definition included patients whose biochemical response to therapy would currently be 
classified as incomplete (stimulated Tg levels ≥ 10 ng/ml) or indeterminate (stimulated levels > 1 and < 10 ng/mL) [23].  
In 80% of the cases, repetition of the stimulated Tg assay at some point during follow-up (median: 5.2 years after 
the initial assay) revealed levels below 1 ng/mL, while imaging findings remained persistently negative, thereby allowing 
these patients to be re-classified as disease-free, as defined by the 2009 ATA Guidelines [4]. In the remaining 20%, the most 
recent stimulated serum Tg level recorded (median 4.8 years after the first assay) was still above 1 ng/mL, although only 1 
of these patients had developed structural evidence of disease. These outcomes were unchanged at the final follow-up visit 
(median 8.2 years after the initial assessment, range: 3.5 – 19.5 years): no evidence of structural disease had emerged in any 
of the patients re-classified as disease-free or in the 17 whose stimulated Tg levels remained > 1 ng/mL in the absence of 
localizable disease.  
Several other retrospective studies have explored the significance of detectable Tg production in the absence of 
localizable disease. Reported outcomes in PTC patient populations with these characteristics vary widely [6-10] depending 
on the cut-off used to define detectable Tg production and the specific features of the study cohort (including tumor 
characteristics, initial risk of recurrence, use of additional radioiodine treatment, duration of follow-up). Yim et al. [9], for 
example, retrospectively analyzed 186 cases of differentiated thyroid cancer (DTC) with stimulated Tg levels ≥ 2 ng/mL 
roughly 1 year after thyroidectomy and RRA. Repeat stimulated Tg assays during follow-up (i.e., 1-2 years after the first 
assay) allowed 45 (24%) of these patients to be reclassified as disease-free. A similar picture emerged from the retrospective 
study by Pitoia et al. [10]. They examined a smaller cohort of 32 patients whose only anomaly at the first follow-up visit 
was a stimulated Tg level of > 1 ng/mL. Six (19%) were subsequently reclassified as disease-free on the basis of negative 
results in the repeat stimulated Tg assay. In all 6 cases, the initial stimulated Tg level had been ≤ 1.9 ng/mL, and assay 
negativization occurred within 2.5 years.  
These figures are in stark contrast with the 80% rate of patients who became disease-free during our follow-up. 
The results will obviously be influenced by the Tg threshold used for study enrolment, and the one used by Yim et al. [9] 
was twice as high as the one we chose. However, the roots of the discrepancy between the disease-free rates that emerged 
during follow-up lie mainly in the clinical profiles of the populations studied. Almost two-thirds of the patients in our cohort 
were initially classified as low-risk, as opposed to less than 40% of the cohort examined by Pitoia et al. [10]. In addition, the 
proportion of their cases that were considered high-risk was 7 times that of our cohort (15% vs. 2%). Similar considerations 
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apply to the patients analyzed by Yim et al. [9], 155 (83%) of whom had lymph node metastases at diagnosis (vs. 19 [21%] 
in our study).  
Although retrospective studies like these are bound to vary in terms of cohort characteristics, it is important to note 
that the risk category distribution of the patients in our cohort (Table 1) is much more consistent with those reported in large 
unselected series of DTC patients [3,24,25]. It is also compatible with figures from the SEER Program database, which 
show that almost 68% of thyroid cancers are confined to the thyroid gland at diagnosis (and are therefore considered at low 
risk for recurrence according to the ATA risk stratification system), while 26% and 4% spread to regional lymph nodes or 
distant sites, respectively [26].   
This distinction is important because the utility of repeating stimulated serum Tg assays in patients with suspicious 
findings that are exclusively biochemical is related mainly to its ability to identify patients who have been cured rather than 
those with persistent or recurrent cancer. Indeed, while the negative predictive value of TSH-stimulated Tg assay 
approaches 100%, the positive predictive value is dismally low (26%) [27]. Patients who meet the criteria for classification 
as disease free/excellent response have a minimal risk of recurrence, estimated at 1-2% [28,29]. They can thus be followed 
with more relaxed protocols, which offer important potential advantages in terms of patient stress and health-care spending. 
While the results of the studies cited above indicate that only a minority of patients with exclusively biochemical 
abnormalities stand to benefit by this downgrading of risk, our experience indicates that in a more or less typical cohort of 
patients with PTC, in which low-risk predominates, repetition of the stimulated Tg assay can markedly reduce the number 
of patients who actually require close, more costly follow-ups.  
In our cohort, negativization of the stimulated Tg assay during follow-up displayed no significant association with 
the initial ATA risk class or the radioiodine dose used for remnant ablation. However, it was significantly more common in 
the subgroup whose initial stimulated Tg value was > 1 ng/mL but < 10 ng/mL (i.e., within the so-called indeterminate 
range) than in the subgroup with initial values that met the criteria for an incomplete biochemical response. This finding is 
consistent with the results reported by Pitoia et al. [10]. In their study, all cases of assay negativization occurred in patients 
whose initial levels were between 1.5 and 1.9 ng/mL. Yim et al. also observed that rates of negativization declined as the 
initial stimulated Tg level rose [9].  
The main limitations of our study are related to its retrospective, multicenter design. Because the cohort was 
composed of patients diagnosed over a period of 16 years in 8 different centers, baseline stimulated Tg levels were 
measured with several different radioimmunometric assays. The fact that all assays used in this cohort had functional 
sensitivities of 1 ng/mL or less (inclusion criterion) allowed us to retrospectively dichotomize the results as 
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detectable/undetectable using the evidence-based cut-off value recommended by the ATA [4]. Use of a categorical rather 
than continuous variable to express Tg levels precluded quantitative analysis of the changes in stimulated Tg over time, but 
our findings clearly confirm the validity of this cut-off for predicting recurrence. The same cut-off was used regardless of 
whether Tg was assayed after LT4 withdrawal or rhTSH injection, a practice that is fully consistent with recommendations 
of the ATA [4] and widely used in clinical settings, where the administration of exogenous TSH is gradually replacing 
thyroid hormone withdrawal. Several groups, however, have shown that Tg levels measured during hormone withdrawal are 
significantly higher than those observed under rhTSH stimulation [30, 31]. These findings suggest that in the 44 patients in 
our cohort whose initial and final Tg assays were performed after LT4 withdrawal and rhTSH stimulation, respectively, 
some cases of assay normalization might be related to the lower intensity TSH stimulation used in the second assay. False 
negativity of this type is in our opinion unlikely. First of all, while Tg measured after LT4-withdrawal consistently exceeds 
that observed in the same patient under rhTSH stimulation, this difference rarely (7% of cases) results in discordant 
classification of the two specimens as positive / negative using the 1 ng/mL cut-off  [30]. Second, in our cohort the 
stimulated Tg negativation rate in this subgroup whose assays were performed under different types of stimulation (36/44, 
82%) is almost identical to that observed in the cohort as a whole (68/86, 80%). For these reasons, the high proportion of 
patients reclassified as disease free in our study is probably a reliable estimate.    
The median interval between the first and final stimulated Tg assays in our cohort was 5.1 years , and the patients 
identified as disease-free at this point remained persistently negative in imaging studies during the remainder of follow-up 
(median 9.6 years). It is impossible to draw any definite conclusions on the optimal timing of repeat stimulated Tg assays on 
the basis of our findings. Nonetheless, from a cost-benefit viewpoint, the 5-year follow-up visit appears to be a reasonable 
choice. First, our previous experience shows that the vast majority of disease recurrences are detected within this time frame 
[3].  However, as noted earlier, the goal of re-testing is not to detect recurrence but to identify patients who can be 
considered disease-free (i.e., patients whose previously positive assay results probably reflected the presence of normal 
thyroid tissue remnants or even small nests of neoplastic cells that are still viable but destined to succumb with time to the 
effects of the initial treatment). In this context, it is interesting to note that in populations not subjected to RRA, basal Tg 
production declines spontaneously, and by year 5, 80% of these patients have undetectable levels [32, 5]. In general, then, 
earlier re-testing is likely to be associated with lower rates of assay normalization. The intervals between the first and final 
stimulated Tg assays in our cohort varied widely, but it is important to note that the median length was not significantly 
different between patients with Tg negativization and patients with Tg > 1 ng/mL at last assessment. In all probability, the 
increasing use of more sensitive Tg assays will eventually eliminate the need to assess Tg production under TSH 
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stimulation, and the cost of assessing serum Tg to identify patients who are disease-free will be substantially reduced. 
However, a validated cut-off level that optimally identifies these patients is still not available for these new assays [27, 33-
35].  
In conclusion, up to one third of PTC patients treated with thyroidectomy and RRA will have detectable stimulated 
Tg levels with no structural evidence of disease at 1 year. Our findings show that, in cases that fall within this “diagnostic 
gray zone,” continued monitoring of stimulated Tg levels should be considered a key component of follow-up, not because 
of its capacity to identify patients with persistent/recurrent disease, which is in fact limited, but because it allows the 
confident exclusion of this outcome in a substantial proportion of this population.  
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Table 1. Baseline characteristics of the study cohort a  
 
Patient characteristics Study cohort              
 (n=86) 
Age (yrs) - median (range) 43.9 (15-87) 
Females – no. (%) 66 (78) 
Tumor size (mm) - median (range) 19 (2-60) 
Multifocal tumors - no. (%) 35 (41) 
Extrathyroidal extension - no. (%) 
- none 
- microscopic (T3) 
- macroscopic (T4) 
 
61 (71) 
24 (28) 
1 (1) 
Lymph node metastases - no. (%) 19 (21) 
Distant metastases - no. (%) 1 (1) 
131I ablation dose activity (mCi) – median (range) 66 (15-145) 
ATA risk class - no. (%) 
- low 
- intermediate 
- high  
 
54 (63) 
30 (35) 
2 (2) 
Initial postoperative findings (1 year) 
Serum Tg levels - median (range) 
- Basal  
- Stimulated b 
Post-treatment WBSc 
- No uptake observed 
- Uptake confined to thyroid bed 
- Uptake outside the thyroid bed 
 
 
0.71 (0.01-2.8) 
2.1 (1.05-27.9) 
 
56 (66) 
29 (34) 
-- 
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Abbreviations: ATA, American Thyroid Association; mCi, millicurie; Tg, thyroglobulin; TSH, thyroid-stimulating 
hormone. 
a Characteristics are those documented at the time of initial treatment (total thyroidectomy + radioiodine remnant ablation) 
with the exception of serum thyroglobulin levels, which are those measured at the first follow-up visit (6 to 18 months after 
initial treatment). 
b Assay performed according to standardized protocols (ATA 2009) after thyroid hormone withdrawal in 78 cases and after 
rhTSH injection in 8. 
c Data available for 85/86 patients  
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Table 2. Baseline patient characteristics associated with negativization of TSH-stimulated Tg assay during follow-up 
 
Patient characteristics a Last TSH Stimulated Tg assay 
result b 
P value 
Tg-NEG 
 (n=68) 
Tg-POS 
(n=18) 
Initial postoperative TSH Stimulated Tg level - no. (%) 
- > 1 and < 10 ng/mL 
- ≥ 10 ng/ml 
 
65 (95.6) 
3 (4.4) 
 
13 (72.2) 
5 (27.8) 
 
0.006 
ATA risk class - no. (%) 
- low 
- intermediate 
- high  
 
44 (64.7) 
22 (32.3) 
2 (3) 
 
10 (55.6) 
8 (44.4) 
0 (0) 
 
0.52 
131I ablation dose activity (mCi) – median (range) 67.3 (15-145) 63.3 (15-106) 0.9 
 
Abbreviations: Tg, thyroglobulin; TSH, thyroid-stimulating hormone; ATA, American Thyroid Association; mCi, 
millicurie. 
a See Table 1 
b Tg-NEG (≤ 1 ng/mL); Tg-POS (> 1 ng/mL)  
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Figure legends 
 
Figure 1. Study cohort selection procedure and follow-up findings. A total of 365 cases of PTC satisfied the initial 
criteria for inclusion in the study. At the first postoperative visit (6-18 months after radioiodine remnant ablation [RRA]), 93 
of these individuals were Tg-POS/Imaging-NEG. After exclusion of the 7 who received additional radioiodine therapy, the 
study cohort contained 86 patients. Abbreviations: Tg-NEG: stimulated serum Tg levels ≤ 1 ng/mL; Tg-POS: stimulated 
serum Tg levels > 1 ng/mL; Imaging-NEG: no suspicious findings whatsoever on neck ultrasound or any other imaging 
studies that were performed; Imaging-POS: suspicious / indeterminate findings on neck ultrasound. In all cases reported as 
Imaging-POS, the presence of structural disease was subsequently confirmed by biopsy and/or surgical pathology. The 
follow-up durations (from first to final post-treatment assessment) for this cohort ranged from 3.5 to 19.5 years (median 8.2 
years). 
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